Additionally, for cancer, several clinical trials are ongoing, e.g., targeting G12D-mutated KRAS mRNA in advanced pancreatic cancer, targeting STAT3 mRNA in metastatic NSCLC, or HSP27 mRNA in lung cancer, metastatic bladder cancer, or prostate cancer [151]. This evidence concerns the gene KRAS and lung carcinoma.